Moderna, Inc. (MRNA) shares climbed 12.3% to $172.94 as of September 22, 2026, a sharp gain from the prior close of $154.04. BestStocks flagged the session as a major change for MRNA. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
MRNA climbed 12.3% to $172.94
MRNA climbed 12.3% in its latest session, moving from $154.04 to $172.94.
ValuationMedium confidence
Rel. volume
1.6×
Above Avg
Vs peers
—
No comparable peers
Market cap
$68.6B
NASDAQ Global Select
Analyst target
$116
-33.1% vs price
Price chart
Aug 24 – Sep 21
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Moderna, Inc. investors
For Moderna, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Strong 12.3% price move with conviction; Positive price momentum. Weighing against that: Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga); MRNA moved -6.40% from its $57.54 open to a $53.86 close on 2026-08-06. Wall Street's consensus price target sits at $115.70, implying -33.1% downside from $172.94. Over the past 90 days analysts logged 3 upgrades and 1 downgrade. BestStocks rates the overall signal quality medium (63/100). With earnings roughly 44 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $172.94, up $18.90 (+12.27%) from the previous close of $154.04. The session traded on 1.6× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $135.61 and $172.94, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
The consensus analyst price target on Moderna, Inc. (MRNA) is $115.70, 33.1% below the recent $172.94. Over the past 90 days analysts logged 3 upgrades, 11 maintains, and 1 downgrade. Here is how the bullish and bearish cases on MRNA line up.
▲ The bullish case
+The Street's most bullish target is $245.00 (+41.7%).
+3 analyst upgrades in the past 90 days, most recently Argus Research to Buy (2026-08-28).
+Strong 12.3% price move with conviction.
+Positive price momentum.
+Moderna surged +9.08% to $149.02 following investor enthusiasm over successful late-stage clinical trial results for its personalized mRNA cancer vaccine developed with Merck, which showed high effectiveness in preventing recurrence in high-risk melanoma patients (Yahoo Finance).
▼ The bearish case
−The consensus analyst price target of $115.70 sits 33.1% below the recent $172.94, so the average target sees limited room to run.
−The most bearish analyst target is $25.00 (-85.5%).
−1 analyst downgrade in the past 90 days, most recently Rothschild & Co to Sell (2026-09-03).
−Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga).
−MRNA moved -6.40% from its $57.54 open to a $53.86 close on 2026-08-06.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Moderna rose 8.98% to $158.70, extending a 137% one-month rally driven by sector-wide cancer vaccine momentum (247wallst.com). The gain occurred without fresh company disclosures; peers BioNTech and Novavax also edged higher. Volume was 11.0M shares at 150 minutes into the session, tracking at 0.89x expected levels for this time of day—normal activity.
Moderna surged +9.08% to $149.02 following investor enthusiasm over successful late-stage clinical trial results for its personalized mRNA cancer vaccine developed with Merck, which showed high effectiveness in preventing recurrence in high-risk melanoma patients (Yahoo Finance). The breakthrough validates mRNA technology's commercial potential beyond infectious diseases, driving heavy institutional buying and keeping the stock near multi-month highs.
Material / Earnings2026-09-04-2.2%
Moderna, Inc. (MRNA) moved -5.25% from $153.62 to $145.55 on 2026-09-04. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting typical trading activity.
Moderna surged 8.41% to $152.14 following a successful Phase 3 melanoma vaccine trial in collaboration with Merck, according to Yahoo Finance and Barron's. The trial represents a major clinical milestone for the company's cancer vaccine pipeline. Volume of 17.9M shares is tracking at 0.71x the time-adjusted average, consistent with typical midday trading patterns.
Moderna shares fell 6.90% to $147.87 intraday, with volume at 1.24x the time-adjusted expected level. The evidence identifies this move as a tracked event on 2026-08-26 cited by Morningstar and Yahoo Finance, though the specific driver is not disclosed in the available sources. The decline occurs ahead of the company's November earnings report (consensus EPS estimate: -$1.38).
Moderna surged +10.98% to $154.14 on fresh analyst upgrades and continued momentum from its cancer vaccine breakthrough. Wolfe Research upgraded the stock this morning, building on Bank of America's $170 price-target raise last week and the company's landmark Phase 3 trial success for its personalized mRNA melanoma vaccine (developed with Merck), per Benzinga and Yahoo Finance.
Moderna rallied 7.18% to $142.89 as traders repositioned following a historic 177% surge earlier in the week sparked by positive late-stage melanoma vaccine trial results with Merck (reported by 247wallst.com and Yahoo Finance). The stock is experiencing volatile whipsaw trading with volume at 5.27x the time-adjusted average, driven by short-term traders and algorithmic funds resetting positions after Wednesday's breakout and Thursday's pullback; no fresh clinical or corporate data emerged on Friday.
Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga). The collapse follows a prior rally that had pushed MRNA up 177% and triggered a spillover rally in semiconductor stocks; volume is elevated at 7× normal levels for this time of session, signaling heavy institutional and retail liquidation.
In-depth MRNA event analyses
Permanent, dated analyses of MRNA's most significant sessions.
MRNA climbed 12.3% to $172.94. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MRNA stock rise?
MRNA gained 12.27% ($18.90) versus the prior close of $154.04, last trading at $172.94 on 1.6× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2026-11-05 — about 44 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $115.70, about 33.1% below the current $172.94. Over the past 90 days, analysts recorded 3 upgrades, 11 maintains, and 1 downgrade.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
